The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma

Antonio Russo, Daniela Petriella, Ettore Fistola, Gianmauro Numico, Evaristo Maiello, Stefania Tommasi, Nicola Silvestris, Giuseppe Colucci, Giuseppe Tonini, Daniele Santini, Daniele Santini

Risultato della ricerca: Articlepeer review

16 Citazioni (Scopus)


Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development. Copyright © 2010 S. Karger AG.
Lingua originaleEnglish
pagine (da-a)69-74
Numero di pagine6
Stato di pubblicazionePublished - 2010

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma'. Insieme formano una fingerprint unica.

Cita questo